The company maintains a disciplined capital structure with a debt-to-equity ratio consistently near 0.20, providing a stable foundation despite asset valuation swings.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 0 | 2.91B | 3.03B | 3.05B | 3.16B | 1.99B | 2.14B | 2.18B | 2.02B | 1.98B | 1.84B | 1.78B | 1.72B | 1.76B | 1.94B | 1.8B | 1.98B | 1.56B | 1.09B | 1.03B | 1.13B | 1.01B | 908.46M | 655.4M | 465.8M | 430.83M | 369.67M | 378.7M | 235.4M | 227.4M | 198.5M |
| Cash & Short-Term Investments | 0 | 1.54B | 1.66B | 1.61B | 1.79B | 869.92M | 991.12M | 1.11B | 844.8M | 754.98M | 839.44M | 786.27M | 697.63M | 608.92M | 921.07M | 813.12M | 1.03B | 744.81M | 243.47M | 223.74M | 488.08M | 413.06M | 361.63M | 148.64M | 27.73M | 47.13M | 13.95M | 17.1M | 10.1M | 10.8M | 9.4M |
| Cash Only | 0 | 531.8M | 488.1M | 403.8M | 434.21M | 470.78M | 662.21M | 660.67M | 431.53M | 383.82M | 456.26M | 457.55M | 413.25M | 331.55M | 463.39M | 574.23M | 906.55M | 649.94M | 204.52M | 161.76M | 223.61M | 296.72M | 195.73M | 65.39M | 27.73M | 47.13M | 13.95M | 17.1M | 10.1M | 10.8M | 9.4M |
| Short-Term Investments | 0 | 1.01B | 1.18B | 1.2B | 1.36B | 399.13M | 328.91M | 453.97M | 413.27M | 371.15M | 383.18M | 328.72M | 284.38M | 277.37M | 457.69M | 238.88M | 118.64M | 94.88M | 38.95M | 61.98M | 264.47M | 116.34M | 165.9M | 83.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 472.5M | 452.5M | 489M | 494.64M | 423.54M | 419.42M | 392.67M | 392.44M | 464.85M | 372.35M | 391.49M | 377.64M | 422.66M | 398.74M | 398.67M | 388M | 345.73M | 339.65M | 358.08M | 292.97M | 247.19M | 261.24M | 234.09M | 212.28M | 194.4M | 182.24M | 193.9M | 106M | 97M | 97.8M |
| Days Sales Outstanding | 49.91 | 66.76 | 64.35 | 66.82 | 64.43 | 52.9 | 60.14 | 62 | 62.55 | 78.55 | 65.71 | 70.76 | 63.37 | 72.34 | 70.33 | 70.18 | 73.49 | 70.73 | 70.27 | 89.45 | 83.94 | 76.4 | 87.48 | 85.15 | 86.79 | 86.8 | 91.64 | 128.8 | 87.55 | 82.94 | 85.24 |
| Inventory | 0 | 740.7M | 760M | 780.5M | 719.32M | 572.24M | 622.25M | 554.01M | 583.82M | 594.8M | 524.96M | 490.22M | 471M | 516.25M | 455.12M | 433.51M | 398.1M | 351.21M | 375.62M | 321.01M | 253.04M | 212.34M | 205.51M | 190.26M | 166.37M | 139.18M | 132.52M | 126.3M | 92.4M | 91.4M | 69.7M |
| Days Inventory Outstanding | 170.02 | 218.1 | 233.58 | 228.95 | 212.61 | 162.61 | 205.03 | 191.73 | 199.95 | 223.18 | 206.01 | 199.31 | 172.51 | 197.47 | 182.91 | 176.67 | 173.89 | 163.42 | 170.98 | 174.96 | 164.52 | 145 | 156.29 | 158.55 | 158.46 | 142.57 | 161.2 | 202.46 | 185.82 | 196.36 | 155.03 |
| Other Current Assets | 0 | 13.8M | 30.7M | 31.7M | 29.16M | 15.65M | 16.42M | 16.5M | 15.18M | 15.88M | 16.76M | 15.25M | 61.75M | 79.02M | 69.26M | 53.78M | 54.44M | 43.1M | 41.41M | 36.45M | 35.86M | 67.12M | 25.73M | 31.06M | 37.05M | 27.54M | 0 | 41.4M | 26.9M | 28.2M | 21.6M |
| Total Non-Current Assets | 0 | 7.67B | 6.33B | 9.25B | 10.34B | 15.81B | 10.83B | 5.83B | 3.59B | 2.3B | 2.01B | 1.93B | 1.62B | 1.63B | 1.51B | 1.3B | 1.09B | 973.18M | 943.32M | 942.62M | 466.39M | 418.37M | 463.16M | 337.2M | 254.91M | 253.2M | 276.61M | 290.2M | 131.9M | 124.5M | 86.4M |
| Property, Plant & Equipment | 0 | 709.9M | 688.6M | 723.7M | 679.55M | 716.44M | 693.51M | 701.21M | 508.69M | 493.5M | 488.61M | 437.69M | 428.84M | 414.4M | 416.94M | 349.5M | 333.62M | 302.42M | 300.73M | 271.56M | 189.63M | 180.26M | 202.32M | 179.12M | 142.24M | 132.97M | 119.03M | 125.9M | 82.1M | 78.7M | 71.9M |
| Fixed Asset Turnover | 4.77x | 3.64x | 3.73x | 3.69x | 4.12x | 4.08x | 3.67x | 3.30x | 4.50x | 4.38x | 4.23x | 4.61x | 5.07x | 5.15x | 4.96x | 5.93x | 5.78x | 5.90x | 5.87x | 5.38x | 6.72x | 6.55x | 5.39x | 5.60x | 6.28x | 6.15x | 6.10x | 4.36x | 5.38x | 5.42x | 5.82x |
| Goodwill | 0 | 579.8M | 410.5M | 413.6M | 406.5M | 347.3M | 291.9M | 264.1M | 219.8M | 506.1M | 477.1M | 495.9M | 500.4M | 517.8M | 495.4M | 468.9M | 363.98M | 327.63M | 321.82M | 328.44M | 119.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 174.3M | 293.6M | 320.5M | 332.1M | 253.9M | 199.5M | 145.5M | 133.1M | 174.1M | 161.6M | 214M | 254.2M | 266.2M | 260.9M | 259.5M | 203.88M | 204.78M | 228.59M | 210.3M | 44.6M | 141.72M | 171.91M | 81.75M | 69.52M | 75.87M | 90.97M | 105.4M | 18.6M | 27.7M | 0 |
| Long-Term Investments | 16.74B | 6.1B | 4.84B | 7.7B | 8.83B | 14.39B | 9.56B | 4.64B | 2.66B | 1.03B | 830.79M | 719.84M | 389.31M | 377.87M | 293.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 102.3M | 101.9M | 94.9M | 94.6M | 104.19M | 86.72M | 79.64M | 70.3M | 94.95M | 47.85M | 64.62M | 52.1M | 55.08M | 24.44M | 209.53M | 172.96M | 125.08M | 79.82M | 111.89M | 103.57M | 82.39M | 82.76M | 55.1M | 43.15M | 44.35M | 66.61M | 58.9M | 31.2M | 18.1M | 14.5M |
| Total Assets | 0 | 10.58B | 9.36B | 12.3B | 13.5B | 17.8B | 12.97B | 8.01B | 5.61B | 4.27B | 3.85B | 3.71B | 3.34B | 3.39B | 3.44B | 3.1B | 3.06B | 2.54B | 2.04B | 1.97B | 1.6B | 1.43B | 1.37B | 992.6M | 720.7M | 684.03M | 646.28M | 668.9M | 367.3M | 351.9M | 284.9M |
| Asset Turnover | 0.34x | 0.24x | 0.27x | 0.22x | 0.21x | 0.16x | 0.20x | 0.29x | 0.41x | 0.51x | 0.54x | 0.54x | 0.65x | 0.63x | 0.60x | 0.67x | 0.63x | 0.70x | 0.87x | 0.74x | 0.80x | 0.83x | 0.79x | 1.01x | 1.24x | 1.20x | 1.12x | 0.82x | 1.20x | 1.21x | 1.47x |
| Asset Growth % | -90.18% | 12.95% | -23.86% | -8.91% | -24.15% | 37.21% | 61.98% | 42.73% | 31.31% | 10.97% | 3.8% | 11.03% | -1.4% | -1.59% | 11.2% | 1.11% | 20.78% | 24.47% | 3.33% | 23.52% | 11.89% | 4.01% | 38.18% | 37.73% | 5.36% | 5.84% | -3.38% | 82.11% | 4.38% | 23.52% | -0.07% |
| Total Current Liabilities | 917M | 517M | 467.8M | 522.8M | 568.71M | 680.94M | 631.54M | 905.5M | 450.8M | 502.7M | 471.32M | 441.35M | 446.76M | 487.47M | 472.4M | 459.12M | 666.63M | 419.97M | 418.03M | 414.17M | 319.53M | 319.24M | 315.38M | 239.25M | 222.01M | 199.11M | 189.31M | 202.5M | 97.2M | 100.8M | 79.1M |
| Accounts Payable | 133.1M | 129M | 122.3M | 144.6M | 135.04M | 141.94M | 139.45M | 107.01M | 122.45M | 135.18M | 133.11M | 122.39M | 128.61M | 148.51M | 130.87M | 129.12M | 113.44M | 92.99M | 117.98M | 96.47M | 83.41M | 72.95M | 71.19M | 53.99M | 75.23M | 64.9M | 62.97M | 64.7M | 26.7M | 32.4M | 21.3M |
| Days Payables Outstanding | 38.81 | 37.98 | 37.59 | 42.42 | 39.91 | 40.34 | 45.95 | 37.04 | 41.94 | 50.72 | 52.24 | 49.76 | 47.11 | 56.81 | 52.6 | 52.62 | 49.55 | 43.27 | 53.71 | 52.58 | 54.23 | 49.82 | 54.14 | 45 | 71.65 | 66.48 | 76.59 | 103.71 | 53.69 | 69.61 | 47.38 |
| Short-Term Debt | 436.7M | 37.9M | 1.2M | 500K | 465K | 489K | 1.3M | 425.7M | 493K | 420K | 334K | 298K | 265K | 1.79M | 1.75M | 814K | 233.18M | 5.13M | 9.58M | 15.63M | 3.04M | 3.34M | 9.46M | 10.42M | 7.49M | 9.93M | 18.15M | 22M | 9.4M | 10.8M | 5.6M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 52.21M | 50.85M | 42.47M | 33.73M | 26.94M | 28.23M | 31M | 29.68M | 26.72M | 26.39M | 26.29M | 24.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 347.2M | 141.2M | 147.2M | 161.6M | 117.44M | 127.94M | 131.1M | 86.81M | 101.22M | 127.29M | 115.39M | 101.78M | 102.58M | 116.57M | 113.04M | 114.79M | 245.13M | 232.84M | 225.87M | 230.1M | 100.34M | 161.88M | 116.35M | 69.02M | 67.08M | 65.84M | 108.2M | 115.8M | 61.1M | 57.6M | 52.2M |
| Current Ratio | 0.00x | 5.62x | 6.48x | 5.83x | 5.55x | 2.92x | 3.39x | 2.41x | 4.49x | 3.93x | 3.91x | 4.03x | 3.84x | 3.61x | 4.10x | 3.92x | 2.96x | 3.72x | 2.62x | 2.48x | 3.54x | 3.16x | 2.88x | 2.74x | 2.10x | 2.16x | 1.95x | 1.87x | 2.42x | 2.26x | 2.51x |
| Quick Ratio | 0.00x | 4.19x | 4.85x | 4.34x | 4.29x | 2.08x | 2.40x | 1.80x | 3.19x | 2.75x | 2.80x | 2.92x | 2.79x | 2.55x | 3.14x | 2.97x | 2.37x | 2.88x | 1.72x | 1.71x | 2.74x | 2.49x | 2.23x | 1.94x | 1.35x | 1.46x | 1.25x | 1.25x | 1.47x | 1.35x | 1.63x |
| Cash Conversion Cycle | 181.12 | 246.88 | 260.35 | 253.35 | 237.12 | 175.17 | 219.22 | 216.7 | 220.56 | 251.01 | 219.49 | 220.31 | 188.78 | 213 | 200.65 | 194.22 | 197.83 | 190.88 | 187.54 | 211.84 | 194.23 | 171.59 | 189.63 | 198.71 | 173.6 | 162.88 | 176.25 | 227.54 | 219.68 | 209.69 | 192.89 |
| Total Non-Current Liabilities | 2.02B | 2.61B | 2.33B | 3.04B | 3.32B | 3.43B | 2.46B | 1.35B | 1.14B | 840.07M | 800.02M | 777.86M | 709.36M | 714.6M | 955.56M | 893.31M | 855.62M | 836.67M | 548.59M | 585.74M | 457.1M | 449.37M | 459.36M | 257.54M | 115.61M | 201.04M | 212.35M | 246.3M | 55.8M | 54.4M | 22.3M |
| Long-Term Debt | 138.6M | 1.34B | 1.2B | 1.2B | 1.2B | 10.51M | 1.3M | 2.4M | 438.94M | 434.58M | 434.19M | 433.88M | 435.71M | 435.62M | 732.41M | 731.7M | 731.1M | 737.92M | 445.98M | 441.81M | 425.63M | 425.69M | 425.98M | 225.84M | 105.77M | 188.42M | 203.36M | 239.2M | 42.3M | 39M | 6.7M |
| Capital Lease Obligations | 483.8M | 154.4M | 131.4M | 165.5M | 153.6M | 175.94M | 186.13M | 187.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 3.77B | 1.06B | 818M | 1.48B | 1.77B | 3.06B | 2.08B | 997.79M | 553.24M | 222.21M | 225.3M | 233.47M | 154.92M | 162.11M | 115.05M | 85.52M | 59.74M | 42.89M | 42.57M | 51.22M | 7.51M | 2.28M | 24.77M | 14.8M | 9.84M | 12.62M | 8.99M | 7M | 13.4M | 15.5M | 15.6M |
| Other Non-Current Liabilities | 1B | 53.4M | 177.2M | 195M | 195.93M | 182.19M | 196.93M | 160.9M | 147.77M | 183.28M | 140.54M | 110.51M | 118.73M | 116.87M | 108.09M | 76.09M | 64.78M | 55.85M | 60.04M | 92.72M | 23.96M | 21.4M | 8.6M | 16.9M | 0 | 0 | 0 | 100K | 100K | -100K | 0 |
| Total Liabilities | 2.94B | 3.12B | 2.79B | 3.56B | 3.89B | 4.11B | 3.09B | 2.25B | 1.59B | 1.34B | 1.27B | 1.22B | 1.16B | 1.2B | 1.43B | 1.35B | 1.52B | 1.26B | 966.62M | 999.9M | 776.63M | 768.61M | 774.73M | 496.79M | 337.62M | 400.15M | 401.66M | 448.8M | 153M | 155.2M | 101.4M |
| Total Debt | 575.3M | 1.53B | 1.37B | 1.41B | 1.39B | 223.38M | 225.74M | 651.18M | 439.43M | 435M | 434.52M | 434.18M | 435.98M | 437.4M | 734.16M | 732.51M | 964.28M | 743.05M | 455.56M | 457.43M | 428.67M | 429.03M | 435.44M | 236.26M | 113.25M | 198.35M | 221.51M | 261.2M | 51.7M | 49.8M | 12.3M |
| Net Debt | 575.3M | 999.2M | 886.6M | 1B | 953.88M | -247.41M | -436.47M | -9.49M | 7.9M | 51.18M | -21.74M | -23.37M | 22.72M | 105.85M | 270.78M | 158.28M | 57.73M | 93.11M | 251.03M | 295.67M | 205.06M | 132.31M | 239.7M | 170.86M | 85.52M | 151.22M | 207.55M | 244.1M | 41.6M | 39M | 2.9M |
| Debt / Equity | 0.08x | 0.21x | 0.21x | 0.16x | 0.14x | 0.02x | 0.02x | 0.11x | 0.11x | 0.15x | 0.17x | 0.17x | 0.20x | 0.20x | 0.36x | 0.42x | 0.63x | 0.58x | 0.43x | 0.47x | 0.52x | 0.65x | 0.73x | 0.48x | 0.30x | 0.70x | 0.91x | 1.19x | 0.24x | 0.25x | 0.07x |
| Debt / EBITDA | -1.83x | 3.22x | 3.27x | 2.91x | 2.10x | 0.35x | 0.40x | 1.61x | 14.92x | 1.64x | 2.22x | 1.45x | 1.45x | 1.38x | 1.86x | 1.76x | 2.45x | 2.23x | 1.63x | 2.26x | 2.13x | 2.43x | 2.64x | 1.26x | 0.65x | 1.29x | 2.01x | 3.43x | 0.99x | 1.08x | 0.21x |
| Net Debt / EBITDA | -1.83x | 2.10x | 2.11x | 2.07x | 1.45x | -0.39x | -0.78x | -0.02x | 0.27x | 0.19x | -0.11x | -0.08x | 0.08x | 0.33x | 0.69x | 0.38x | 0.15x | 0.28x | 0.90x | 1.46x | 1.02x | 0.75x | 1.45x | 0.91x | 0.49x | 0.99x | 1.89x | 3.21x | 0.80x | 0.85x | 0.05x |
| Interest Coverage | -2.49x | 5.52x | -46.90x | -16.20x | -122.43x | 3514.25x | 225.97x | 97.56x | 22.39x | 5.25x | 2.78x | 7.72x | 6.94x | 2.83x | 5.50x | 5.63x | 4.46x | 4.95x | 5.45x | 4.82x | 5.44x | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 6.85B | 7.45B | 6.57B | 8.74B | 9.62B | 13.69B | 9.88B | 5.76B | 4.02B | 2.93B | 2.58B | 2.49B | 2.19B | 2.19B | 2.02B | 1.74B | 1.54B | 1.28B | 1.07B | 971.69M | 819.54M | 657.97M | 596.89M | 495.81M | 383.09M | 283.88M | 244.62M | 220.1M | 214.3M | 196.7M | 183.5M |
| Equity Growth % | 11.17% | 13.46% | -24.85% | -9.09% | -29.74% | 38.52% | 71.67% | 43.15% | 37.2% | 13.61% | 3.56% | 13.97% | -0.07% | 8.49% | 15.54% | 13.23% | 20.43% | 19.48% | 10.18% | 18.57% | 24.55% | 10.23% | 20.39% | 29.42% | 34.95% | 16.05% | 11.14% | 2.71% | 8.95% | 7.19% | 16.8% |
| Book Value per Share | 254.15 | 273.22 | 232.84 | 299.26 | 322.82 | 453.03 | 327.58 | 190.67 | 133.00 | 97.56 | 87.00 | 84.69 | 75.01 | 75.65 | 70.37 | 61.28 | 54.72 | 45.97 | 38.74 | 35.60 | 30.41 | 24.68 | 22.53 | 18.84 | 14.73 | 11.16 | 9.96 | 9.05 | 8.67 | 7.92 | 7.35 |
| Total Shareholders' Equity | 6.85B | 7.45B | 6.57B | 8.74B | 9.62B | 13.69B | 9.88B | 5.76B | 4.02B | 2.93B | 2.58B | 2.49B | 2.19B | 2.19B | 2.02B | 1.74B | 1.54B | 1.26B | 1.04B | 971.69M | 819.54M | 657.97M | 596.89M | 495.81M | 383.09M | 283.88M | 244.62M | 220.1M | 214.3M | 196.7M | 183.5M |
| Common Stock | 0 | 0 | 0 | 0 | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 2K | 12.48M | 12.5M | 0 | 0 | 0 |
| Retained Earnings | 7.65B | 8.18B | 7.42B | 9.26B | 9.9B | 13.53B | 9.27B | 5.47B | 3.72B | 1.83B | 1.83B | 1.81B | 1.69B | 1.61B | 1.53B | 1.36B | 1.18B | 996.2M | 851.58M | 762.07M | 674.07M | 570.81M | 489.25M | 421.01M | 344.84M | 276.55M | 231.82M | 201M | 189.8M | 167.2M | 151M |
| Treasury Stock | 0 | -1.01B | -772.1M | -632.5M | -263.59M | -106.29M | -99.91M | -38.4M | -49.13M | -217K | -101K | -101K | -101K | -101K | -101K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.86M | -5.42M | -7.4M | 0 | 0 | 0 |
| Accumulated OCI | -235.4M | -189.1M | -538.2M | -336M | -466.82M | -175.55M | 282.46M | -87.35M | -46.96M | 738.79M | 417.77M | 382.14M | 218.94M | 340.72M | 274.53M | 198.69M | 198.02M | 133.08M | 65.16M | 110.99M | 67.23M | 27.05M | 58M | 32.63M | 2.1M | -22.99M | -13.39M | -4.7M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 535K | 445K | 3.82M | 19.49M | 29.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sartorius equity valuation volatility
According to recent financial disclosures, Bio-Rad maintains a remarkably stable equity base, which has fluctuated between $6.6 billion and $9.1 billion over the last ten quarters, reflecting a conservative capital structure that remains largely insulated from the operational headwinds currently impacting the broader life sciences sector.
The company's balance sheet trajectory suggests a defensive posture, characterized by minimal reliance on external leverage to fund operations. While total assets have experienced periodic contraction, the underlying equity remains robust, indicating that the firm is well-positioned to weather prolonged periods of stagnant organic growth.
As reported in quarterly filings, Bio-Rad maintains a disciplined debt-to-equity ratio that has consistently remained near 0.20, signaling a highly conservative approach to leverage that provides the company with significant financial flexibility compared to more aggressive peers in the medical device and life science instrumentation space.
The company's minimal debt load suggests that management prioritizes balance sheet preservation over aggressive capital expansion. This low leverage profile serves as a critical buffer, allowing the firm to navigate potential volatility in its core markets without the immediate pressure of refinancing or interest coverage concerns.
Based on reported figures, Bio-Rad exhibits a robust liquidity profile with current ratios consistently exceeding 5.0, which provides a substantial cushion against the lumpy working capital requirements and inventory management challenges inherent in its global clinical diagnostics and life science reagent distribution business models.
The elevated current ratio suggests that the company maintains an ample supply of liquid assets to meet short-term obligations, even during periods of operational disruption. Investors should monitor whether this high liquidity is a strategic choice to support potential M&A or a byproduct of inefficient working capital management.
As indicated by the company's balance sheet data, the significant equity stake in Sartorius AG introduces substantial volatility into total asset values, which may obscure the underlying health and performance of Bio-Rad's core clinical diagnostics and life science operations for investors analyzing the firm's intrinsic value.
The mark-to-market accounting treatment of the Sartorius investment creates a persistent distortion that makes headline asset figures unreliable for assessing operational efficiency. Analysts should treat this equity position as a separate financial asset rather than a reflection of the company's core manufacturing or research capabilities.
Quick answers to the most common questions about buying BIO stock.
As of 2025, Bio-Rad Laboratories, Inc. (BIO) had total assets of $10.58B including $2.91B in current assets.
Bio-Rad Laboratories, Inc. (BIO) carries total debt of $1.53B, offset by $1.54B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Bio-Rad Laboratories, Inc. (BIO) has total shareholders' equity (book value) of $7.45B ($273.22 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Bio-Rad Laboratories, Inc. (BIO) reported a current ratio of 5.62x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.